Skip Navigation


JAC Advance Access originally published online on February 7, 2006
Journal of Antimicrobial Chemotherapy 2006 57(4):709-713; doi:10.1093/jac/dkl034
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
57/4/709    most recent
dkl034v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rodés, B.
Right arrow Articles by Soriano, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rodés, B.
Right arrow Articles by Soriano, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy

Berta Rodés*, Julie Sheldon, Carlos Toro, Victoria Jiménez, Miguel Ángel Álvarez and Vincent Soriano

Molecular Biology Laboratory, Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain

Received 22 August 2005; returned 1 November 2005; revised 2 December 2005; accepted 24 January 2006

* Corresponding author. Tel: +34-91-453-2586; Fax: +34-91-733-6614; E-mail: brodes.hciii{at}salud.madrid.org

Background: Current protease inhibitors (PIs) are designed against HIV-1, and information on their performance against HIV-2 clinical isolates is scarce.

Methods: Genetic and phenotypic analyses using all available PIs were performed in five HIV-2 primary isolates from two patients on regular follow-up who failed PI-HAART.

Results: HIV-2 proteases before therapy showed amino acids associated with resistance in HIV-1 (pro10V, pro32I, pro36I, pro46I, pro47V, pro71V and pro73A). Phenotypic results showed that indinavir, saquinavir, lopinavir and tipranavir had full activity against wild-type HIV-2. However, a susceptibility reduction was noticed for nelfinavir (6.6-fold) and amprenavir (31-fold). During therapy with lopinavir, one patient developed proV47A, which translated into high-level resistance (13.4- to 41-fold) to indinavir, lopinavir and amprenavir, and hypersusceptibility to saquinavir. All isolates from the other patient had multiple mutations after several PIs failed (proV10I, proV33L, proI54M, proV71I and proI82F). The acquisition of mutations 54M and 82F along with naturally occurring changes resulted in multi-PI-resistant viruses (33- to >1000-fold), and only saquinavir retained full activity.

Conclusions: Naturally occurring secondary mutations or polymorphisms in the HIV-2 protease may decrease the activity of nelfinavir and amprenavir. Moreover, upon selection of primary resistance mutations, pre-existing secondary changes might play an important role in the acquisition of a multi-PI resistance phenotype in HIV-2.

Keywords: retroviruses , resistance , HAART


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
D. Desbois, B. Roquebert, G. Peytavin, F. Damond, G. Collin, A. Benard, P. Campa, S. Matheron, G. Chene, F. Brun-Vezinet, et al.
In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors
Antimicrob. Agents Chemother., April 1, 2008; 52(4): 1545 - 1548.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
R. A. Smith, G. S. Gottlieb, D. J. Anderson, C. L. Pyrak, and B. D. Preston
Human Immunodeficiency Virus Types 1 and 2 Exhibit Comparable Sensitivities to Zidovudine and Other Nucleoside Analog Inhibitors In Vitro
Antimicrob. Agents Chemother., January 1, 2008; 52(1): 329 - 332.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. Masse, X. Lu, T. Dekhtyar, L. Lu, G. Koev, F. Gao, H. Mo, D. Kempf, B. Bernstein, G. J. Hanna, et al.
In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 2 with Decreased Susceptibility to Lopinavir
Antimicrob. Agents Chemother., September 1, 2007; 51(9): 3075 - 3080.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
S. Jallow, S. Kaye, M. Schutten, E. Brandin, J. Albert, S. J. McConkey, T. Corrah, H. Whittle, G. Vanham, S. Rowland-Jones, et al.
Development and Evaluation of an Oligonucleotide Ligation Assay for Detection of Drug Resistance-Associated Mutations in the Human Immunodeficiency Virus Type 2 pol Gene
J. Clin. Microbiol., May 1, 2007; 45(5): 1565 - 1571.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. Ntemgwa, B. G. Brenner, M. Oliveira, D. Moisi, and M. A. Wainberg
Natural Polymorphisms in the Human Immunodeficiency Virus Type 2 Protease Can Accelerate Time to Development of Resistance to Protease Inhibitors
Antimicrob. Agents Chemother., February 1, 2007; 51(2): 604 - 610.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
B. Rodes, J. Sheldon, C. Toro, L. Cuevas, E. Perez-Pastrana, I. Herrera, and V. Soriano
Quantitative Detection of Plasma Human Immunodeficiency Virus Type 2 Subtype A RNA by the Nuclisens EasyQ Assay (Version 1.1)
J. Clin. Microbiol., January 1, 2007; 45(1): 88 - 92.
[Abstract] [Full Text] [PDF]

Home page
 Int J EpidemiolHome page
S. Eholie and X. Anglaret
Commentary: Decline of HIV-2 prevalence in West Africa: good news or bad news?
Int. J. Epidemiol., October 1, 2006; 35(5): 1329 - 1330.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.